Isa Oboirien: Why Might Factor XI Inhibition Work Differently in Stroke and ACS?
Isa Oboirien, Higher Specialty Trainee at Health Education England, shared a post on LinkedIn:
“Why might Factor XI inhibition work differently in stroke and ACS?
The contrasting signals with factor XIa inhibition may reflect differences in thrombotic biology.
Recurrent coronary events after ACS are predominantly platelet-driven, arising from plaque rupture or erosion with intense platelet activation.
Contemporary PCI and potent dual antiplatelet therapy already target this pathway effectively, potentially leaving little residual coagulation-mediated risk for additional FXIa inhibition to modify.
Indeed, LIBREXIA-ACS showed no reduction in cardiovascular death, MI or ischaemic stroke with milvexian.
In contrast, recurrent ischaemic stroke is mechanistically heterogeneous, involving artery-to-artery thromboembolism, thrombin generation and fibrin-rich clot propagation, alongside platelet activation.
FXI may therefore contribute more importantly to thrombus amplification within cerebral circulation.
The encouraging symptomatic-stroke signal in AXIOMATIC-SSP and OCEANIC-STROKE trials, coupled with minimal intracranial bleeding, raises the intriguing possibility that FXIa inhibition may be better suited to cerebral than coronary thrombosis – a hypothesis that LIBREXIA-STROKE will ultimately test.”
Stay updated with Hemostasis Today.
-
Aug 31, 2026, 15:41Adrien Jossart: Acute Thrombotic Storm Following Single Heparin Bolus
-
Aug 31, 2026, 15:36Bernhard Gerber: Myocardial Platelet Activation Linked to Microvascular Obstruction After STEMI
-
Aug 31, 2026, 15:34Higher Fibrinogen γ′ Linked to Increased Risk of Recurrent Arterial Thrombosis – Journal of Thrombosis and Haemostasis
-
Aug 31, 2026, 15:21Ney Carter Borges: Anticoagulation Versus Antiplatelet Therapy After TAVI ESC 26
-
Aug 31, 2026, 15:13Nahid A. Qushmaq: MicroRNAs as Prognostic Biomarkers in Septic Patients
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?